Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its complex mechanisms of immune evasion. HIV-1 envelope glycoproteins are poorly recognized by the immune system, which means that potent broadly neutralizing antibodies (bnAbs) are only infrequently induced in the setting of HIV-1 infection or through vaccination. Thus, the biology of HIV-1-host interactions necessitates novel strategies for vaccine development to be designed to activate and expand rare bnAb-producing B cell lineages and to select for the acquisition of critical improbable bnAb mutations. Here we discuss strategies for the induction of potent and broad HIV-1 bnAbs and outline the steps that may be necessary for ultimate success.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Immunology
- Humans
- HIV-1
- HIV Infections
- HIV Antibodies
- Broadly Neutralizing Antibodies
- Antigens, Viral
- Antibodies, Neutralizing
- AIDS Vaccines
- 3204 Immunology
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Immunology
- Humans
- HIV-1
- HIV Infections
- HIV Antibodies
- Broadly Neutralizing Antibodies
- Antigens, Viral
- Antibodies, Neutralizing
- AIDS Vaccines
- 3204 Immunology